J.B.H. Warneck

532 total citations
17 papers, 391 citations indexed

About

J.B.H. Warneck is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, J.B.H. Warneck has authored 17 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Organic Chemistry and 5 papers in Pharmacology. Recurrent topics in J.B.H. Warneck's work include Phosphodiesterase function and regulation (9 papers), Phenothiazines and Benzothiazines Synthesis and Activities (5 papers) and Synthesis and Catalytic Reactions (4 papers). J.B.H. Warneck is often cited by papers focused on Phosphodiesterase function and regulation (9 papers), Phenothiazines and Benzothiazines Synthesis and Activities (5 papers) and Synthesis and Catalytic Reactions (4 papers). J.B.H. Warneck collaborates with scholars based in United Kingdom, Germany and United States. J.B.H. Warneck's co-authors include John G. Montana, Reinhold Tacke, John Mills, Graham A. Showell, J.O. Daiss, Christian Burschka, Matthew J. Barnes, Hazel J. Dyke, David J. Miller and Richard Conroy and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, British Journal of Pharmacology and Toxicology and Applied Pharmacology.

In The Last Decade

J.B.H. Warneck

17 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.B.H. Warneck United Kingdom 13 232 170 52 28 28 17 391
Norman L. Colbry United States 12 199 0.9× 174 1.0× 56 1.1× 30 1.1× 46 1.6× 19 401
Kinfe K. Redda United States 13 333 1.4× 120 0.7× 65 1.3× 13 0.5× 14 0.5× 57 481
Russell F. Graceffa United States 8 115 0.5× 101 0.6× 23 0.4× 29 1.0× 11 0.4× 9 273
Dipam Patel India 13 205 0.9× 168 1.0× 33 0.6× 21 0.8× 29 1.0× 24 436
Michael J. Ashton United Kingdom 11 135 0.6× 236 1.4× 81 1.6× 57 2.0× 44 1.6× 19 409
Christopher A. Teleha United States 13 393 1.7× 234 1.4× 58 1.1× 16 0.6× 8 0.3× 32 668
Clint D. W. Brooks United States 9 139 0.6× 100 0.6× 86 1.7× 40 1.4× 16 0.6× 17 298
Paul W. Collins United States 11 418 1.8× 140 0.8× 140 2.7× 14 0.5× 17 0.6× 19 648
Maria Fridén‐Saxin Sweden 10 343 1.5× 127 0.7× 142 2.7× 18 0.6× 10 0.4× 12 495
Ramón Alajarı́n Spain 15 519 2.2× 238 1.4× 35 0.7× 12 0.4× 13 0.5× 33 664

Countries citing papers authored by J.B.H. Warneck

Since Specialization
Citations

This map shows the geographic impact of J.B.H. Warneck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.B.H. Warneck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.B.H. Warneck more than expected).

Fields of papers citing papers by J.B.H. Warneck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.B.H. Warneck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.B.H. Warneck. The network helps show where J.B.H. Warneck may publish in the future.

Co-authorship network of co-authors of J.B.H. Warneck

This figure shows the co-authorship network connecting the top 25 collaborators of J.B.H. Warneck. A scholar is included among the top collaborators of J.B.H. Warneck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.B.H. Warneck. J.B.H. Warneck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Barnes, Matthew J., Christian Burschka, Richard Conroy, et al.. (2011). Silicon Analogues of the Nonpeptidic GnRH Antagonist AG‐045572: Syntheses, Crystal Structure Analyses, and Pharmacological Characterization. ChemMedChem. 6(11). 2070–2080. 11 indexed citations
2.
Warneck, J.B.H., Matthew J. Barnes, John Mills, et al.. (2008). Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret. Toxicology and Applied Pharmacology. 232(3). 369–375. 19 indexed citations
3.
Showell, Graham A., Matthew J. Barnes, J.O. Daiss, et al.. (2006). (R)-Sila-venlafaxine: A selective noradrenaline reuptake inhibitor for the treatment of emesis. Bioorganic & Medicinal Chemistry Letters. 16(9). 2555–2558. 45 indexed citations
4.
Barnes, Michael R., Richard Conroy, David J. Miller, et al.. (2006). Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: A new use of silicon bioisosteres in medicinal chemistry. Bioorganic & Medicinal Chemistry Letters. 17(2). 354–357. 55 indexed citations
5.
Daiss, J.O., Christian Burschka, John Mills, et al.. (2006). Synthesis, crystal structure analysis, and pharmacological characterization of desmethoxy-sila-venlafaxine, a derivative of the serotonin/noradrenaline reuptake inhibitor sila-venlafaxine. Journal of Organometallic Chemistry. 691(17). 3589–3595. 5 indexed citations
6.
Daiss, J.O., Christian Burschka, John Mills, et al.. (2006). Sila-venlafaxine, a Sila-Analogue of the Serotonin/Noradrenaline Reuptake Inhibitor Venlafaxine:  Synthesis, Crystal Structure Analysis, and Pharmacological Characterization. Organometallics. 25(5). 1188–1198. 73 indexed citations
7.
8.
Heinrich, T., Christian Burschka, J.B.H. Warneck, & Reinhold Tacke. (2003). Synthesis and Pharmacological Properties of Silicon-Containing 1,4-Dihydropyridine Derivatives:  Calcium Channel Antagonists and α1 Adrenoceptor Antagonists of the Sila-niguldipine Type. Organometallics. 23(3). 361–366. 19 indexed citations
9.
Billah, Motasim, George M. Buckley, Nicola J. Cooper, et al.. (2002). 8-Methoxyquinolines as PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 12(12). 1617–1619. 18 indexed citations
10.
Buckley, George M., Nicola Cooper, Hazel J. Dyke, et al.. (2002). 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma. Bioorganic & Medicinal Chemistry Letters. 12(12). 1613–1615. 12 indexed citations
11.
Buckley, George M., Nicola J. Cooper, Richard Davenport, et al.. (2002). 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 Inhibitors: A Potential Treatment for Asthma. Bioorganic & Medicinal Chemistry Letters. 12(3). 509–512. 17 indexed citations
12.
Billah, M. Motasim, Nicola J. Cooper, Michael Minnicozzi, et al.. (2002). Pharmacology of N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline Carboxamide (SCH 351591), a Novel, Orally Active Phosphodiesterase 4 Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 302(1). 127–137. 27 indexed citations
13.
Buckley, George M., Nicola Cooper, Hazel J. Dyke, et al.. (2000). 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma. Bioorganic & Medicinal Chemistry Letters. 10(18). 2137–2140. 15 indexed citations
14.
Cooper, Nicola J., Mauro Martins Teixeira, J.B.H. Warneck, et al.. (1999). A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. British Journal of Pharmacology. 126(8). 1863–1871. 19 indexed citations
15.
Cooper, Nicola, Hazel J. Dyke, Lewis Gowers, et al.. (1998). PDE4 inhibitors: New xanthine analogues. Bioorganic & Medicinal Chemistry Letters. 8(20). 2925–2930. 7 indexed citations
16.
Montana, John G., George M. Buckley, Nicola Cooper, et al.. (1998). Aryl sulfonamides as selective PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 8(19). 2635–2640. 19 indexed citations
17.
Cooper, Nicola, Lewis Gowers, Alan F. Haughan, et al.. (1998). Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma. Bioorganic & Medicinal Chemistry Letters. 8(19). 2629–2634. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norman L. Colbry Breakdown of academic impact, for papers by Kinfe K. Redda Breakdown of academic impact, for papers by Russell F. Graceffa Breakdown of academic impact, for papers by Dipam Patel Breakdown of academic impact, for papers by Michael J. Ashton Breakdown of academic impact, for papers by Christopher A. Teleha Breakdown of academic impact, for papers by Clint D. W. Brooks Breakdown of academic impact, for papers by Paul W. Collins Breakdown of academic impact, for papers by Maria Fridén‐Saxin Breakdown of academic impact, for papers by Ramón Alajarı́n
Rankless by CCL
2026